Richter and Australian peer Acrux said Acruxʼs drug for treating menopause symptoms, called Lenzetto, had received multiple marketing approvals in European territories, triggering the milestone payments.
These approvals of Lenzetto were granted after the European decentralized procedure (DCP) was completed with the first country approval triggering a milestone payment of $1 mln and the second and third approvals triggering milestone payments of $500,000 each, Richter said.
Initial launches are planned for the first half of 2016, following pricing and reimbursement approvals, it added.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
